Follow
Ariele Viacava Follis
Ariele Viacava Follis
Director of Structural Biology, Rome Therapeutics
Verified email at rometx.com
Title
Cited by
Cited by
Year
Many players in BCL-2 family affairs
T Moldoveanu, AV Follis, RW Kriwacki, DR Green
Trends in biochemical sciences 39 (3), 101-111, 2014
5182014
Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc
DI Hammoudeh, AV Follis, EV Prochownik, SJ Metallo
Journal of the American Chemical Society 131 (21), 7390-7401, 2009
2542009
Improved low molecular weight Myc-Max inhibitors
H Wang, DI Hammoudeh, AV Follis, BE Reese, JS Lazo, SJ Metallo, ...
Molecular cancer therapeutics 6 (9), 2399-2408, 2007
2532007
Discoveries and controversies in BCL‐2 protein‐mediated apoptosis
JH Zheng, A Viacava Follis, RW Kriwacki, T Moldoveanu
The FEBS journal 283 (14), 2690-2700, 2016
2502016
Large-scale assessment of binding free energy calculations in active drug discovery projects
CEM Schindler, H Baumann, A Blum, D Böse, HP Buchstaller, ...
Journal of Chemical Information and Modeling 60 (11), 5457-5474, 2020
2242020
Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules
AV Follis, DI Hammoudeh, H Wang, EV Prochownik, SJ Metallo
Chemistry & biology 15 (11), 1149-1155, 2008
2062008
Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling
V Csizmok, A Viacava Follis, RW Kriwacki, JD Forman-Kay
Chemical Reviews, 2016
2052016
PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis
AV Follis, JE Chipuk, JC Fisher, MK Yun, CR Grace, A Nourse, K Baran, ...
Nature chemical biology 9 (3), 163-168, 2013
1982013
Discovery of evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases
RD Caldwell, H Qiu, BC Askew, AT Bender, N Brugger, M Camps, ...
Journal of Medicinal Chemistry 62 (17), 7643-7655, 2019
1202019
Pin1-induced proline isomerization in cytosolic p53 mediates BAX activation and apoptosis
AV Follis, F Llambi, P Merritt, JE Chipuk, DR Green, RW Kriwacki
Molecular cell 59 (4), 677-684, 2015
1092015
Discovery of novel Myc− Max heterodimer disruptors with a three-dimensional pharmacophore model
G Mustata, AV Follis, DI Hammoudeh, SJ Metallo, H Wang, ...
Journal of medicinal chemistry 52 (5), 1247-1250, 2009
1012009
The DNA-binding domain mediates both nuclear and cytosolic functions of p53
AV Follis, F Llambi, L Ou, K Baran, DR Green, RW Kriwacki
Nature structural & molecular biology 21 (6), 535-543, 2014
962014
Small-molecule perturbation of competing interactions between c-Myc and Max
AV Follis, DI Hammoudeh, AT Daab, SJ Metallo
Bioorganic & medicinal chemistry letters 19 (3), 807-810, 2009
722009
Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
AV Follis, F Llambi, H Kalkavan, Y Yao, AH Phillips, CG Park, FM Marassi, ...
Nature chemical biology 14 (5), 458-465, 2018
502018
Intrinsic protein flexibility in regulation of cell proliferation: advantages for signaling and opportunities for novel therapeutics
AV Follis, CA Galea, RW Kriwacki
Fuzziness: Structural Disorder in Protein Complexes, 27-49, 2012
392012
Identification and characterization of an allosteric inhibitory site on dihydropteroate synthase
DI Hammoudeh, M Daté, MK Yun, W Zhang, VA Boyd, A Viacava Follis, ...
ACS Chemical Biology 9 (6), 1294-1302, 2014
372014
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit
H Qiu, L Liu-Bujalski, RD Caldwell, AV Follis, A Gardberg, A Goutopoulos, ...
Bioorganic & Medicinal Chemistry Letters 28 (17), 2939-2944, 2018
242018
Centrality of drug targets in protein networks
A Viacava Follis
BMC bioinformatics 22, 1-29, 2021
172021
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk
R Caldwell, L Liu-Bujalski, H Qiu, I Mochalkin, R Jones, C Neagu, ...
Bioorganic & Medicinal Chemistry Letters 28 (21), 3419-3424, 2018
172018
Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors
H Qiu, Z Ali, A Bender, R Caldwell, YY Chen, Z Fang, A Gardberg, ...
Bioorganic & medicinal chemistry 40, 116163, 2021
122021
The system can't perform the operation now. Try again later.
Articles 1–20